您搜索了: demyeliniserende (丹麦语 - 英语)

første demyeliniserende hændelse
first demyelinating event

kronisk inflammatorisk demyeliniserende polyneuropati (cidp)*
chronic inflammatory demyelinating polyneuropathy (cidp)

nyligt opståede demyeliniserende sygdomme i centralnervesystemet.
prescribers should exercise caution in considering the use of trudexa in patients with pre-existing or recent-onset central nervous system demyelinating disorders. i dic

demyeliniserende sygdomme (f. eks. optisk neuritis)
cutaneous vasculitis

guillain-barré syndrom, kronisk inflammatorisk demyeliniserende
demyelinating disorders (such as guillain-barré syndrome, chronic

enkelt demyeliniserende hændelse som tyder på dissemineret sklerose
single clinical event suggestive of multiple sclerosis

patienter med kronisk inflammatorisk demyeliniserende polyneuropati (cidp).
patients with chronic inflammatory demyelinating polyneuropathy (cidp).

enkelt demyeliniserende hændelse som tyder på dissemineret sklerose:
single clinical event suggestive of ms:

forværring af kliniske symptomer og/ eller radiografiske tegn på demyeliniserende sygdom.
of clinical symptoms and/ or radiographic evidence of demyelinating disease.

reaktivering af hepatitis b demyeliniserende sygdomme (f. eks. optisk neuritis)
adverse reaction reactivation of hepatitis b demyelinating disorders (e. g. optic neuritis) interstitial lung disease, including pulmonary

-patienter med en enkelt demyeliniserende hændelse med en aktiv inflammatorisk proces, der er
· patients with a single demyelinating event with an active inflammatory process, if it is severe

bivirkning reaktivering af hepatitis b demyeliniserende sygdomme (f. eks. optisk neuritis)
adverse reaction reactivation of hepatitis b demyelinating disorders (e. g. optic neuritis) interstitial lung disease, including pulmonary

rebif blev også sammenlignet med placebo hos 515 patienter, som havde haft et enkelt demyeliniserende tilbagefald.
rebif has also been compared with placebo in 515 patients who had experienced a single attack of demyelination.

centrale og perifere demyeliniserende hændelser er blevet set forholdsvis sjældent og meget sjældent i forbindelse ved brug af enbrel.
central and peripheral demyelinating events have been seen rarely and very rarely, respectively, with enbrel use.

der er rapporteret om hændelser med demyeliniserende lidelser og ascenderende perifer neuropati, der ligner guillain- barré syndrom
there have also been reports of events associated with demyelination, and ascending peripheral neuropathies similar in appearance to guillain-barré syndrome.

lægen bør udvise forsigtighed, når behandling med humira overvejes til patienter med allerede eksisterende eller nyligt opståede demyeliniserende sygdomme i centralnervesystemet.
prescribers should exercise caution in considering the use of humira in patients with pre-existing or recent-onset central nervous system demyelinating disorders.

lægen bør udvise forsigtighed, når behandling med trudexa overvejes til patienter med allerede eksisterende eller nyligt opståede demyeliniserende sygdomme i centralnervesystemet. mi
prescribers should exercise caution in considering the use of trudexa in patients with pre-existing or recent-onset central nervous system demyelinating disorders. i dic

bivirkning tarmperforation reaktivering af hepatitis b demyeliniserende sygdomme (f. eks. opticus neuritis, guillain barré syndrom)
adverse reaction intestinal perforation reactivation of hepatitis b demyelinating disorders (e. g. optic neuritis, guillain-barré syndrome)

før initiering af humira og regelmæssigt under behandlingen bør der foretages en neurologisk udredning for at vurdere allerede eksisterende eller udvikling af demyeliniserende sygdomme hos patienter med non-infektiøs intermediær uveitis
neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of humira therapy and regularly during treatment to assess for pre- existing or developing central demyelinating disorders.

i den tredje undersøgelse med 383 patienter, som havde oplevet et enkelt demyeliniserende attak, undersøgtes effekten af avonex sammenlignet med placebo med hensyn til reduktion af risikoen for et nyt attak.
the third study, in 383 patients who had experienced a single demyelinating attack, looked at the effectiveness of avonex compared with a placebo in reducing the risk of a second attack.